Optimal timing of thoracic radiotherapy with osimertinib in unresectable EGFR-mutant non-small cell lung cancer
- 1Department of Oncology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi 545005, P.R. China
Abstract
Osimertinib is standard first-line therapy for EGFR-mutant non-small cell lung cancer (NSCLC); however, the optimal timing of combined thoracic radiotherapy (TRT) remains unclear. The aim of the present study was to investigate the relationship between the interval from osimertinib treatment to TRT interval and the survival outcomes, defining an optimal therapeutic window for unresectable EGFR-mutant NSCLC. Data from 175 patients with stage IIIB/IV EGFR-mutant NSCLC receiving first-line osimertinib and consolidation TRT were retrospectively analyzed. Cox regression and restricted cubic spline (RCS) models, inverse probability of treatment weighting, and left-truncated and landmark analyses were performed. At a median follow-up time of 25.3 months, each 1-day delay in the osimertinib-to-TRT interval was identified as an independent adverse prognostic factor for locoregional progression-free survival [hazard ratio (HR), 1.02; 95% confidence interval (CI), 1.01-1.02; P<0.001], progression-free survival (HR, 1.01; 95% CI, 1.01-1.02; P<0.001), and overall survival (HR, 1.02; 95% CI, 1.01-1.02; P<0.001). The RCS model revealed a significant non-linear J-shaped association (non-linear P<0.05), with risk peaking between 40 and 102 days. All sensitivity analyses, including inverse probability of treatment weighting, left-truncated immortal time bias adjustment, 3/6/12-month landmark analyses, and osimertinib response adjustment, yielded consistent effect estimates. These findings indicate that the interval between osimertinib and TRT initiation is an independent prognostic factor for EGFR-mutant NSCLC, with a non-linear J-shaped association with survival. TRT initiation within 40 days of osimertinib commencement confers optimal benefit, providing evidence-based guidance for clinical treatment decision-making.
Related
- Survival outcomes of radiotherapy in elderly patients with unresectable stage III hepatocellular carcinoma: a population-based retrospective cohort study
- AI-assisted 3D thoracic body composition analysis identifies candidate imaging markers associated with overall survival in older patients with lung cancer receiving radiotherapy
- Anti-tumor immunotherapy, radiotherapy, and chemotherapy multimodal combination strategies and interactions in unresectable, locally advanced lung cancer: Clinical practice, mechanism, and biomarker research
- Osimertinib Optimal Dosing Through Population Pharmacokinetics in Virtual Patients with NSCLC: An Approach Integrating Multiple Studies.
- Radiotherapy dose escalation for the non-operative management of patients with unresectable locally recurrent rectal cancer (STEP-UP): Study protocol for a multicentre, prospective, open-label feasibility study.
BibTeX
@article{lai2026optimal,
title = {{Optimal timing of thoracic radiotherapy with osimertinib in unresectable EGFR-mutant non-small cell lung cancer}},
author = {Mengting Lai and Yanhua Zhou and Weili Yi and Jian Huang and Zhili Chen and Xin Yin and Li Qin and Dongning Huang},
journal = {Oncology Letters},
year = {2026},
month = oct,
doi = {10.3892/ol.2026.15906},
url = {https://europepmc.org/article/PMC/PMC13717425},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Optimal timing of thoracic radiotherapy with osimertinib in unresectable EGFR-mutant non-small cell lung cancer
AU - Mengting Lai
AU - Yanhua Zhou
AU - Weili Yi
AU - Jian Huang
AU - Zhili Chen
AU - Xin Yin
AU - Li Qin
AU - Dongning Huang
PY - 2026
DA - 2026/10/13
JO - Oncology Letters
DO - 10.3892/ol.2026.15906
UR - https://europepmc.org/article/PMC/PMC13717425
AB - Osimertinib is standard first-line therapy for EGFR-mutant non-small cell lung cancer (NSCLC); however, the optimal timing of combined thoracic radiotherapy (TRT) remains unclear. The aim of the present study was to investigate the relationship between the interval from osimertinib treatment to TRT interval and the survival outcomes, defining an optimal therapeutic window for unresectable EGFR-mutant NSCLC. Data from 175 patients with stage IIIB/IV EGFR-mutant NSCLC receiving first-line osimertinib and consolidation TRT were retrospectively analyzed. Cox regression and restricted cubic spline (RCS) models, inverse probability of treatment weighting, and left-truncated and landmark analyses were performed. At a median follow-up time of 25.3 months, each 1-day delay in the osimertinib-to-TRT interval was identified as an independent adverse prognostic factor for locoregional progression-free survival [hazard ratio (HR), 1.02; 95% confidence interval (CI), 1.01-1.02; P<0.001], progression-free survival (HR, 1.01; 95% CI, 1.01-1.02; P<0.001), and overall survival (HR, 1.02; 95% CI, 1.01-1.02; P<0.001). The RCS model revealed a significant non-linear J-shaped association (non-linear P<0.05), with risk peaking between 40 and 102 days. All sensitivity analyses, including inverse probability of treatment weighting, left-truncated immortal time bias adjustment, 3/6/12-month landmark analyses, and osimertinib response adjustment, yielded consistent effect estimates. These findings indicate that the interval between osimertinib and TRT initiation is an independent prognostic factor for EGFR-mutant NSCLC, with a non-linear J-shaped association with survival. TRT initiation within 40 days of osimertinib commencement confers optimal benefit, providing evidence-based guidance for clinical treatment decision-making.
SN - 1792-1074
SN - 1792-1082
ER -